Press Releases :: Journey Medical Corporation (DERM)

NOW APPROVED: EMROSI™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg

Learn More

Jan 2, 2024

Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million

Dec 6, 2023

Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

Nov 7, 2023

Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Oct 31, 2023

Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023

Oct 20, 2023

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)

Sep 6, 2023

Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations

Aug 8, 2023

Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Aug 2, 2023

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023

Jul 19, 2023

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023

Jul 11, 2023

Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults

rss_feed News RSS